Pfizer is sharing work and discussing development of novel anti-fibrotic therapies.
Public source
Publisher name
Public post
Looking forward to sharing our work and discussing development of novel anti-fibrotic therapies. 👇👇👇
Company
Pfizer
- Industry
- Pharmaceutical Manufacturing
- Location
- New York, US
- Company size
- 10,001+ employees
About Pfizer
We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines
See moreLatest activity
Latest activity from Pfizer
43 signals
Presence & Recognition
Pfizer participated in the ERS 2026 conference in Barcelona, engaging with the global respiratory community through scientific exchange, expert discussions, and collaborations focused on asthma and COPD care.
Presence & Recognition
Pfizer employee Mariam Sultani will speak at the Festival of Biologics Basel 2026 on October 13-15 at Messe Basel.
People
Pfizer is hiring a Systems Immunology translational AI engineer.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Bristol Myers Squibb
Bristol Myers Squibb researchers are advancing the science of pulmonary fibrosis, investigating potential new approaches for people living with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
Research & Knowledge
AstraZeneca
AstraZeneca is investing in science focused on factors contributing to uncontrolled hypertension and interconnected disease.
Research & Knowledge
GSK
GSK accelerated research programmes are looking to target multiple inflammatory pathways, including TSLP and IL-33, to build a diverse portfolio for COPD patients.
Products & Services
NS Pharma, Inc.
NS Pharma, Inc. is presenting nonclinical pharmacology data on NS-863, a potential platelet-derived growth factor inhibitor for treating pulmonary arterial hypertension and interstitial lung disease.
Research & Knowledge
Boehringer Ingelheim